PMID- 33960145
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 12
DP  - 2021 Jun
TI  - Response to first-line treatment predicts progression-free survival benefit of 
      small-cell lung cancer patients treated with anlotinib.
PG  - 3896-3904
LID - 10.1002/cam4.3941 [doi]
AB  - BACKGROUND: Anlotinib significantly extended progression-free survival (PFS) and 
      overall survival (OS) in small-cell lung cancer (SCLC) as third or later line 
      treatment. METHODS: In this study, we retrospectively analyzed the efficacy and 
      safety of anlotinib in the clinical practice and aimed to identify risk factors 
      for predicting the clinical benefit of anlotinib in SCLC patients. 29 SCLC 
      patients treated with anlotinib monotherapy or combination therapy as second or 
      later line treatment were included. PFS, OS, objective response rate (ORR), 
      disease control rate (DCR), and adverse events (AEs) were analyzed. RESULTS: In 
      whole patients, the median PFS was 2.1 months (95% confidence interval (CI): 
      1.1-3.2 months); The ORR and DCR were 10.3% and 48.3%, respectively; The median 
      OS was 7.2 months (95%CI: 3.2-11.2 months). Cox regression analysis demonstrated 
      that response to first-line treatment was the independent risk factor for PFS. 
      The ORR (20.0% vs. 0%) and DCR (53.3% vs. 42.9%) were promoted in patients 
      treated with anlotinib combination therapy comparing to anlotinib monotherapy. 
      The most common AEs were hoarseness, fatigue, decreased appetite, oral mucositis, 
      and anemia. No treatment-related AEs graded 3 or more. CONCLUSION: Anlotinib is 
      an effective option for SCLC patients with tolerable toxicity as second or later 
      line treatment. Patients sensitive to first-line treatment had longer PFS when 
      treated with anlotinib. Anloitnib combined with other therapy increased the 
      efficacy without adding toxicity.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Qin, Boyu
AU  - Qin B
AD  - Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
FAU - Xin, Lingli
AU  - Xin L
AD  - Department of Gynaecology and Obstetrics, PLA Rocket Force Characteristic Medical 
      Center, Beijing, China.
FAU - Hou, Qingxiang
AU  - Hou Q
AD  - Department of Gynaecology and Obstetrics, PLA Rocket Force Characteristic Medical 
      Center, Beijing, China.
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
FAU - Qi, Xiaoguang
AU  - Qi X
AD  - Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
FAU - Wei, Yingtian
AU  - Wei Y
AD  - Department of Radiology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Hu, Yi
AU  - Hu Y
AD  - Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
FAU - Xiong, Qi
AU  - Xiong Q
AUID- ORCID: 0000-0002-7782-6498
AD  - Department of Oncology, General Hospital of Chinese PLA, Beijing, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20210506
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Confidence Intervals
MH  - Female
MH  - Humans
MH  - Indoles/adverse effects/*therapeutic use
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinolines/adverse effects/*therapeutic use
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Small Cell Lung Carcinoma/*drug therapy/mortality
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC8209577
OTO - NOTNLM
OT  - anlotinib
OT  - efficacy
OT  - independent risk factor
OT  - small-cell lung cancer
COIS- The authors declare that there is no conflict of interest.
EDAT- 2021/05/08 06:00
MHDA- 2021/12/25 06:00
PMCR- 2021/05/06
CRDT- 2021/05/07 07:45
PHST- 2021/02/23 00:00 [revised]
PHST- 2020/12/23 00:00 [received]
PHST- 2021/04/08 00:00 [accepted]
PHST- 2021/05/08 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
PHST- 2021/05/07 07:45 [entrez]
PHST- 2021/05/06 00:00 [pmc-release]
AID - CAM43941 [pii]
AID - 10.1002/cam4.3941 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Jun;10(12):3896-3904. doi: 10.1002/cam4.3941. Epub 2021 May 6.